Merck’s Q2 2012 earnings call reveals a nuanced performance, with solid revenue and EPS growth, innovation in the pipeline, and strategic initiatives for long-term value creation. However, the impending Singulair patent expiry and a challenging global healthcare environment present short-term challenges. The stock is likely to experience a modest negative impact over the next 1–2 weeks. [-1]